Apr 03rd 2013 - Edison Investment Research today published a report on Synta Pharmaceuticals entitled "Combination Approach Comes To The Fore". In summary, the report says:
Synta is to focus in future on combination studies for ganetespib, as it launches its pivotal Phase III GALAXY-2 trial of docetaxel±ganetespib in second-line non-small cell lung cancer (NSCLC). The change is likely to mean an early end to the CHIARA study, which examines ganetespib as monotherapy in ALK+ NSCLC. The shift in strategy will also allow it to focus resources on the large GALAXY-2 study, which is now central to the investment case. The publication of the full ITT data from GALAXY-2’s predecessor, GALAXY-1, which are due in June, is the next major catalyst. Our rNPV of Synta is $790m or $11.44/share (basic) or $10.59/share (diluted).
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »